GI Investigator Dr. John Strickler on the Ground Breaking MOUNTAINEER Trial

At the 2022 ESMO World Congress on Gastrointestinal Cancer, Dr. John Strickler presented the results of a groundbreaking trial for colon cancer. The phase 2 study examined the safety and efficacy of tucatinib in combination with trastuzumab or tucatinib alone in patients with HER2-positive metastatic colorectal cancer. This targeted therapy has the potential to change the trajectory and quality of the lives of patients. In this episode, Dr. Strickler discusses the initial challenge of enrolling patients for the trial and how he secured funding to pay for their participation, since many traveled from other parts of the U.S. for the study. Dr. Strickler is a medical oncologist at Duke Health and member of the Duke Cancer Center. ACCRU assisted Dr. Strickler in the initial phase of the trial, helping to enroll patients and manage the study.